Amanda Oliver

Combined BRAF, MEK, and CDK4/6 Inhibition Depletes Intratumoral Immune-Potentiating Myeloid Populations in Melanoma.

Emily J Lelliott, Stefano Mangiola, Kelly M Ramsbottom, Magnus Zethoven, Lydia Lim, Peter KH Lau, Amanda J Oliver, Luciano G Martelotto, Laura Kirby, Claire Martin, Riyaben P Patel, Alison Slater, Carleen Cullinane, Anthony T Papenfuss, Nicole M Haynes, Grant A McArthur, Jane Oliaro, Karen E Sheppard

Journal article  |  2020  |  Cancer Immunology Research

Combined inhibition of BRAF, MEK, and CDK4/6 is currently under evaluation in clinical trials for patients with melanoma harboring..

Tissue-specific tumour microenvironments are an emerging determinant of immunotherapy responses

Amanda J Oliver, Phillip K Darcy, Michael H Kershaw, Clare Y Slaney

Journal article  |  2020  |  Journal of Thoracic Disease

Cross-talk between tumors at anatomically distinct sites

Amanda J Oliver, Phillip K Darcy, Joseph A Trapani, Michael H Kershaw, Clare Y Slaney

Journal article  |  2020  |  The FEBS Journal

Cancer tissue is not homogenous, and individual metastases at different anatomical locations can differ from the primary tumor and..

Macrophage-Derived CXCL9 and CXCL10 Are Required for Antitumor Immune Responses Following Immune Checkpoint Blockade

Imran G House, Peter Savas, Junyun Lai, Amanda XY Chen, Amanda J Oliver, Zhi L Teo, Kirsten L Todd, Melissa A Henderson, Lauren Giuffrida, Emma V Petley, Kevin Sek, Sherly Mardiana, Tuba N Gide, Camelia Quek, Richard A Scolyer, Georgina V Long, James S Wilmott, Sherene Loi, Phillip K Darcy, Paul A Beavis

Journal article  |  2020  |  Clinical Cancer Research

PURPOSE: Response rates to immune checkpoint blockade (ICB; anti-PD-1/anti-CTLA-4) correlate with the extent of tumor immune infil..

Primary and metastatic breast tumors cross-talk to influence immunotherapy responses

Amanda J Oliver, Simon P Keam, Bianca von Scheidt, Damien J Zanker, Aaron J Harrison, Daniela GM Tantalo, Phillip K Darcy, Michael H Kershaw, Clare Y Slaney

Journal article  |  2020  |  OncoImmunology

The presence of a tumor can alter host immunity systematically. The immune-tumor interaction in one site may impact the local immu..

Novel combination immunotherapy for pancreatic cancer: potent anti-tumor effects with CD40 agonist and interleukin-15 treatment

Jonas RM Van Audenaerde, Elly Marcq, Bianca von Scheidt, Ashleigh S Davey, Amanda J Oliver, Jorrit De Waele, Delphine Quatannens, Jinthe Van Loenhout, Patrick Pauwels, Geert Roeyen, Filip Lardon, Clare Y Slaney, Marc Peeters, Michael H Kershaw, Phillip K Darcy, Evelien LJM Smits

Journal article  |  2020  |  Clinical and Translational Immunology

Objectives: With the poorest 5-year survival of all cancers, improving treatment for pancreatic cancer is one of the biggest chall..

Enhancing chimeric antigen receptor T-cell immunotherapy against cancer using a nanoemulsion-based vaccine targeting cross-presenting dendritic cells

Jack D Chan, Bianca von Scheidt, Bijun Zeng, Amanda J Oliver, Ashleigh S Davey, Aesha Ali, Ranjeny Thomas, Joseph A Trapani, Phillip K Darcy, Michael H Kershaw, Riccardo Dolcetti, Clare Y Slaney

Journal article  |  2020  |  Clinical and Translational Immunology

Objectives: Adoptive transfer of chimeric antigen receptor (CAR)-modified T cells is a form of cancer immunotherapy that has achie..